おすすめの製品
ligand
BocA1V2PF2
品質水準
フォーム
powder
反応適合性
reagent type: ligand
官能基
carboxylic acid
保管温度
2-8°C
SMILES記法
C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(O)=O)CC2=CC=C(C=C2)F)=O)=O)C3CCCCC3)=O
InChI
1S/C30H43FN4O7/c1-18(32-29(41)42-30(2,3)4)25(36)34-24(20-9-6-5-7-10-20)27(38)35-16-8-11-23(35)26(37)33-22(28(39)40)17-19-12-14-21(31)15-13-19/h12-15,18,20,22-24H,5-11,16-17H2,1-4H3,(H,32,41)(H,33,37)(H,34,36)(H,39,40)/t18-,22-,23-,24-/m0/s1
アプリケーション
BocA1V2PF2 is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradation and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlights. A C-terminal variant of BocA1V2PF2 is also available as A1V2PF2-NHEt (916714).
BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2
BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2
その他情報
法的情報
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
関連製品
製品番号
詳細
価格
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
917974-BULK:
917974-100MG:
917974-VAR:
最新バージョンのいずれかを選択してください：
Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
Tasuku Ishida et al.
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）